Articles On Memphasys (ASX:MEM)

ASX up as mining gains offset tech and bank losses Silex, Paladin and uranium stocks soar on supply squeeze Goldman cuts Aussie GDP forecast as US tariffs loom   After a soft start to the day, the ASX bounced back and closed the day 0.3% ...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

ASX slipped after early gains, then finished strongly  Energy sector helped offset losses; Quickstep, Sigma Healthcare turned heads Wall Street rallied to record highs after Trump’s win   The ASX swung from gains, to losses at lunchtime,...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

  ASX slips  as US jobs data fuels Wall Street panic Westpac gets a new CEO Newcomers into the ASX200 index include Guzman u Gomez   The ASX stumbled by 0.3% on Monday after the US jobs report fell short on Friday night, causing Wall Str...

Lumos Diagnostics to raise $10 million, with a little help from an iron-ore baron Memphasys is not horsing around as it trials its Felix sperm-separation device for the equine market Medical cannabis and telehealth play Vitura Health says...

ASX likely to fall sharply after Nvidia’s 9.5pc drop Alphabet, Microsoft, and Apple all also took major hits Weak manufacturing data and falling oil prices are heightening fears   The ASX is likely to drop sharply on Wednesday after Nvidi...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

S&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow Jones Indices says large cap companies continued to lead the market in July Consumer discretionary and real estate topped July sector leaders...

ASX rises on Thursday Nine sectors end higher, led by property stocks Small caps led by BEZ   The local benchmark index hit a record high this morning before trimming gains late. The S&P/ASX200 closed up Thursday, gaining 22.40 poi...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX rises on Monday after Wall Street banked a belter on Friday All 11 local sectors higher, InfoTech winning the race for Best in Show Aruma Resources led the small caps winners   The local benchmark moved strongly into positive terri...

Neuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Priority Review Voucher if drug is approved Neuren is also preparing for a key FDA meeting, building on positive trial results    Neuren Phar...

Neuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Priority Review Voucher if drug is approved Neuren is also preparing for a key FDA meeting, building on positive trial results    Neuren Phar...

Good morning, and welcome to Stockhead’s Top 10 at shortly-after-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the t...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

ASX rises +0.5pc driven by tech, banking, and property sectors This comes as US Fed maintains rates, now plans only one cut in 2024 Aussie unemployment drops to 4pc in May, but analysts predict further rises   Aussie shares rose by +0.5%...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX 200’s rally was driven mainly by gold/silver and iron ore stocks Gold prices hit record high as China continues to buy bullion Asian markets rose due to high commodity prices and new stimulus measures    The ASX 200 index rose by +0....

ASX flat on Monday,  ahead of Federal Budget Tuesday night Oil weakness drags Energy sector lower Chinese shares slump on new US tariffs   After advancing 1.5% last week, the ASX200 fell flat on Monday – greenish by 0.01% – dragged down m...

Cash here is becoming like the orange-bellied parrot – highly endangered – despite the folding stuff continuing to be the preferred transactional means of many tradies and their customers. From this month, Macquarie Bank went completely cas...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

By Tim Boreham, Editor ASX code: ((HYD)) Market cap: $4.3m Shares on issue: 254,218,847 Financials (December half 2023): revenue $5.97m (down -17.5%), loss of $3.82m (-$1.96m deficit previously), cash of $847,277 (down -73.5%)* * After bala...

The ASX200 has ended RBA Day comfortably higher Materials lead gains as iron ore prices rise Small Caps led by Pentanet   The ASX has ended Tuesday higher after the Reserve Bank of Australia kept rates on hold for another month. At 4.15 p...

With the RBA’s interest rates decision due tomorrow, the ASX200’s expected to open marginally higher – the top bank’s two-day meeting gets underway this morning. Our market notched a 2.2 per cent slide last week, and American markets had...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  ASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small cap winners led by American Rare Earths and Appen   The benchmark was shot through the heart by CSL this morning leaving everything else in...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

ASX200 closes 0.9pc higher Property stocks and IT sector enjoy huge day Small caps led by DCL   The Australian sharemarket has lifted strongly on Day Two of Trading in November, the Best Month for Trading Ever. Local investors got stuck r...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by...

Australian biotechnology company, Memphasys says a $1.3 million research and development tax refund from the ATO will repay a loan and interest, while the net refund will be reinvested as working capital.

Australian biotechnology company, Memphasys says a $1.3 million research and development tax refund from the ATO will repay a loan and interest, while the net refund will be reinvested as working capital.

Benchmark ASX index closes at new 12-month lows Energy and Materials the worst of 9 dipping ASX sectors on Monday Small caps led by CHM, TON   On Monday Aussie markets rediscovered their nadir of the year. No real surprises, since every n...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Just when all looked lost for a group of parent hopefuls in India, a piece of Australian medical technology developed by Memphasys has turned their dreams of the pitter-patter of tiny feet into reality.

Just when all looked lost for a group of parent hopefuls in India, a piece of Australian medical technology developed by Memphasys has turned their dreams of the pitter-patter of tiny feet into reality.

ASX200 is making a strong run into the weekend – up 1.5 per cent with all sectors ahead.  Seismic testing for Woodside’s (WDS) Scarborough gas project off Western Australia’s northern coast has stalled, despite approvals attained in July...

Memphasys’s (MEM) FELIX sperm separation technology has led to 11 successful pregnancies and births in India with 10 more announced today The company’s FELIX product is a compact box device box that separates the largest sperm from seme...

Memphasys reported 10 new live births in India using its Felix system Ramsay Health Care’s credit rating downgraded by Fitch   Memphasys reports 10 new live births in India Reproductive-focused biotech Memphasys (ASX:MEM) has just reporte...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s Top 10 at shortly-before-11-ish, published shortly after I’ve located my reading glasses and wiped the bacon grease off my fingers at the start of each trading day. It highlights the best (and sometimes worst) performing ASX sto...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...